CAMP

3.42

8.23% 0.26

Dopo l'orario di chiusura: 3.44 0.02 +0.58%

Camp 4 Therapeutics Corp (CAMP)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CAMP Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.16

Aprire:

$3.28

Volume 24 ore:

336.70K

Relative Volume:

1.84

Capitalizzazione di mercato:

$177.59M

Reddito:

$3.50M

Utile/perdita netta:

$-80.40M

Rapporto P/E:

-1.3302

EPS:

-2.5711

Flusso di cassa netto:

$-29.83M

1 W Prestazione:

+3.01%

1M Prestazione:

-18.57%

6M Prestazione:

-10.70%

1 anno Prestazione:

+88.95%

Intervallo 1D:

$3.16

$3.58

Intervallo di 1 settimana:

$2.90

$3.58

Portata 52W:

$1.32

$7.75

Camp 4 Therapeutics Corp Stock (CAMP) Company Profile

Nome

Camp 4 Therapeutics Corp

Settore

Healthcare (1074)

Industria

Biotechnology (599)

Telefono

617-651-8867

Indirizzo

ONE KENDALL SQUARE, CAMBRIDGE, CA

Dipendente

Cinguettio

@calamp

Prossima data di guadagno

2026-08-13

Ultimi documenti SEC

CAMP's Discussions on Twitter

Compare CAMP vs VRTX, REGN, ARGX, RVMD, ALNY

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CAMP Camp 4 Therapeutics Corp	3.42	164.09M	3.50M	-80.40M	-29.83M	-2.5711
VRTX Vertex Pharmaceuticals Inc	479.00	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.17	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	888.82	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.07	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	278.40	36.28B	4.29B	577.22M	641.34M	4.2086

Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-14	Iniziato	Rodman & Renshaw	Buy
2025-10-02	Iniziato	Cantor Fitzgerald	Overweight
2025-09-16	Downgrade	JP Morgan	Overweight → Neutral
2025-05-27	Iniziato	Wedbush	Outperform
2024-11-05	Iniziato	JP Morgan	Overweight
2024-11-05	Iniziato	Piper Sandler	Overweight
2024-11-05	Iniziato	William Blair	Outperform
2022-08-16	Aggiornamento	Craig Hallum	Hold → Buy
2021-12-22	Downgrade	Craig Hallum	Buy → Hold
2021-09-24	Reiterato	Craig Hallum	Buy
2021-06-25	Reiterato	Craig Hallum	Buy
2020-12-18	Downgrade	JP Morgan	Neutral → Underweight
2020-04-17	Aggiornamento	Jefferies	Hold → Buy
2020-03-05	Reiterato	Craig Hallum	Buy
2019-12-20	Reiterato	Craig Hallum	Buy
2019-12-20	Downgrade	First Analysis Sec	Outperform → Neutral
2019-06-28	Aggiornamento	Northland Capital	Market Perform → Outperform
2019-05-29	Downgrade	Goldman	Neutral → Sell
2019-05-01	Reiterato	Craig Hallum	Buy
2019-03-25	Downgrade	JP Morgan	Overweight → Neutral
2019-01-25	Aggiornamento	JP Morgan	Neutral → Overweight
2018-12-21	Aggiornamento	Craig Hallum	Hold → Buy
2018-12-14	Reiterato	B. Riley FBR	Buy
2018-12-11	Downgrade	First Analysis Sec	Strong Buy → Outperform
2018-12-11	Downgrade	Northland Capital	Outperform → Market Perform
2018-11-27	Iniziato	Goldman	Neutral
2018-10-15	Iniziato	Jefferies	Hold
2018-09-28	Reiterato	Craig Hallum	Hold
2018-04-27	Reiterato	Craig Hallum	Hold
2018-03-08	Downgrade	Craig Hallum	Buy → Hold
2018-02-16	Aggiornamento	First Analysis Sec	Equal-Weight → Overweight

Mostra tutto

Camp 4 Therapeutics Corp Borsa (CAMP) Ultime notizie

04:15 AM

CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Forecasts - Yahoo! Finance Canada

04:15 AM

09:00 AM

Camp4 Therapeutics’ lead ASO approved for clinical trials in Australia - BioWorld News

09:00 AM

07:38 AM

CAMP4 receives Australian clearance for SYNGAP1 therapy trial - Investing.com Australia

07:38 AM

07:25 AM

Camp4 Therapeutics Corp secures clinical trial approval for first SYNGAP1 disease-modifying therapy in Australia - Traders Union

07:25 AM

07:02 AM

CAMP4 Therapeutics (CAMP) clears CMP-002 trial in Australia, eyes $50.1M raise - Stock Titan

07:02 AM

07:00 AM

SYNGAP1 Disorder Has No Approved Treatments; CAMP4 Clears Trial - Stock Titan

07:00 AM

04:11 AM